FY2025 Earnings Forecast for MAZE Issued By Lifesci Capital

Maze Therapeutics, Inc. (NASDAQ:MAZE) – Equities research analysts at Lifesci Capital issued their FY2025 earnings per share estimates for Maze Therapeutics in a research note issued to investors on Thursday, December 18th. Lifesci Capital analyst R. Katkhuda forecasts that the company will post earnings of ($2.60) per share for the year. Lifesci Capital currently has a “Strong-Buy” rating on the stock. Lifesci Capital also issued estimates for Maze Therapeutics’ Q4 2025 earnings at ($0.67) EPS.

Several other brokerages have also recently issued reports on MAZE. Wall Street Zen upgraded shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 13th. HC Wainwright lifted their price objective on Maze Therapeutics from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, December 3rd. BTIG Research increased their target price on Maze Therapeutics from $30.00 to $37.00 and gave the stock a “buy” rating in a research report on Friday, September 12th. Wedbush raised their target price on Maze Therapeutics from $35.00 to $36.00 and gave the company an “outperform” rating in a research note on Friday, November 7th. Finally, Wells Fargo & Company started coverage on Maze Therapeutics in a research report on Thursday, December 4th. They set an “overweight” rating and a $55.00 price target on the stock. Three investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $43.38.

Maze Therapeutics Trading Up 0.6%

NASDAQ:MAZE opened at $41.98 on Monday. The company has a 50-day moving average price of $34.82 and a 200-day moving average price of $23.26. Maze Therapeutics has a 12 month low of $6.71 and a 12 month high of $43.29. The stock has a market cap of $2.02 billion and a price-to-earnings ratio of -2.01.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.08.

Hedge Funds Weigh In On Maze Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Frazier Life Sciences Management L.P. purchased a new position in shares of Maze Therapeutics during the first quarter valued at approximately $45,460,000. ARCH Venture Management LLC bought a new position in Maze Therapeutics during the 1st quarter valued at approximately $45,362,000. Matrix Capital Management Company LP bought a new position in Maze Therapeutics during the 1st quarter valued at approximately $27,373,000. Woodline Partners LP purchased a new position in Maze Therapeutics during the first quarter valued at $10,229,000. Finally, Vanguard Group Inc. boosted its holdings in Maze Therapeutics by 218.1% in the third quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company’s stock worth $34,615,000 after acquiring an additional 915,342 shares in the last quarter.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de?risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.